Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: software salesperson who wrote (1472)	4/15/2003 11:12:28 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3044

EU Partner? First, they are looking for best deal that will take care about near term (cash for MLNM and oncology sale presence in EU) and long term (broad cancer market, strong marketing presence). Four candidates (I think it will be EU company): Roche, Novartis, Aventis, and AstraZeneca (I am excluding SKB). I will go with Roche. Interesting for EU market is that Thalidomide is not popular at all in EU so market urgently need new drug for MM. I will speculate that EU will approve Velcade early than US-FDA. Miljenko